Daily Anesthesiology Research Analysis
Top anesthesiology-impact papers today span critical care and data science: a machine-learning framework (COMET) integrates EHR with omics to boost small-cohort analyses; reduced sedation (avoiding continuous neuromuscular blockade) during VV-ECMO for COVID-19 associates with lower 90-day mortality; and adjunctive angiotensin II in catecholamine-resistant vasodilatory shock receiving CRRT is linked to lower ICU and 30-day mortality.
Summary
Top anesthesiology-impact papers today span critical care and data science: a machine-learning framework (COMET) integrates EHR with omics to boost small-cohort analyses; reduced sedation (avoiding continuous neuromuscular blockade) during VV-ECMO for COVID-19 associates with lower 90-day mortality; and adjunctive angiotensin II in catecholamine-resistant vasodilatory shock receiving CRRT is linked to lower ICU and 30-day mortality.
Research Themes
- Sedation strategies and neuromuscular blockade during VV-ECMO
- Adjunct vasopressor therapy (angiotensin II) in catecholamine-resistant shock on CRRT
- EHR–omics multimodal machine learning for precision perioperative medicine
Selected Articles
1. A machine learning approach to leveraging electronic health records for enhanced omics analysis.
COMET is a multimodal transfer-learning framework that pretrains on large EHR datasets and fuses clinical and omics data to improve modeling and discovery in small omics cohorts. Across two independent datasets, COMET outperformed traditional omics-only methods in prediction and biological insight. It enables more granular patient stratification beyond binary case–control labels.
Impact: Methodological advance enabling robust analysis of small perioperative/critical-care omics studies by leveraging ubiquitous EHR data is likely to influence precision anesthesiology research.
Clinical Implications: While not a clinical trial, COMET may accelerate biomarker discovery and risk stratification in perioperative medicine (e.g., predicting delirium, pain phenotypes, or AKI) by enabling more powerful analyses with existing EHR-linked cohorts.
Key Findings
- Introduces COMET, a transfer-learning framework integrating EHR and omics via early and late fusion.
- Across two independent datasets, COMET improved predictive performance versus omics-only analyses.
- COMET enhanced biological discovery and enabled more precise, non-binary patient classifications.
Methodological Strengths
- Transfer learning from large observational EHRs with adaptive fusion (early/late).
- Validation on two independent datasets demonstrating generalizability.
Limitations
- Exact cohort sizes and public code/data availability are not specified in the abstract.
- Clinical utility still requires prospective validation and workflow integration.
Future Directions: Prospective studies embedding COMET into perioperative registries to drive biomarker validation and clinical decision support; broader benchmarking across surgical/anesthesia indications.
Omics studies produce a large number of measurements, enabling the development, validation and interpretation of systems-level biological models. Large cohorts are required to power these complex models; yet, the cohort size remains limited due to clinical and budgetary constraints. We introduce clinical and omics multimodal analysis enhanced with transfer learning (COMET), a machine learning framework that incorporates large, observational electronic health record databases and transfer learning to improve the analysis of small datasets from omics studies. By pretraining on electronic health record data and adaptively blending both early and late fusion strategies, COMET overcomes the limitations of existing multimodal machine learning methods. Using two independent datasets, we showed that COMET improved the predictive modelling performance and biological discovery compared with the analysis of omics data with traditional methods. By incorporating electronic health record data into omics analyses, COMET enables more precise patient classifications, beyond the simplistic binary reduction to cases and controls. This framework can be broadly applied to the analysis of multimodal omics studies and reveals more powerful biological insights from limited cohort sizes.
2. Evaluation of Angiotensin II in Patients With Catecholamine-Resistant Vasodilatory Shock Requiring Continuous Renal Replacement Therapy (ANGEL CRRT).
In CRVS patients on CRRT, adjunctive angiotensin II was associated with lower ICU mortality (aOR 0.438) and 30-day mortality (aOR 0.479) versus standard vasopressors alone, with no significant differences in 72-hour SOFA or time to shock reversal. Fungal infections were more frequent with angiotensin II.
Impact: Targets a high-risk subgroup where vasopressor options are limited; findings support angiotensin II as a potential adjunct in refractory vasodilatory shock with dialysis-level AKI.
Clinical Implications: Consider angiotensin II as adjunct therapy in CRVS patients requiring CRRT, with vigilant antifungal stewardship and infection surveillance; randomized trials are needed before protocol changes.
Key Findings
- Adjunctive angiotensin II associated with lower ICU mortality (61.4% vs 75.4%; adjusted OR 0.438).
- Lower 30-day mortality with angiotensin II (67.1% vs 78.5%; adjusted OR 0.479).
- No significant differences in 72-hour SOFA or time to shock reversal; higher fungal infections with angiotensin II.
Methodological Strengths
- Multicenter cohort with adjusted logistic regression for key confounders.
- Clear inclusion: severe CRVS (NE ≥0.5 mcg/kg/min) on CRRT.
Limitations
- Retrospective design with potential selection bias and residual confounding.
- Antimicrobial exposure and infection surveillance practices may differ between groups.
Future Directions: Prospective randomized trials in CRVS with renal replacement therapy to confirm mortality benefit and characterize infection risks; pharmacoeconomic evaluations.
OBJECTIVE: To compare clinical outcomes of patients with catecholamine-resistant vasodilatory shock (CRVS) receiving continuous renal replacement therapy who receive adjunctive angiotensin II (ANGII) to those who do not. DESIGN: Retrospective cohort analysis. SETTING: Multicenter, single health system consisting of one academic medical center and four community hospitals. PARTICIPANTS: Critically ill adult patients with CRVS (norepinephrine or equivalent dose ≥0.5 mcg/kg/min). INTERVENTIONS: Adjunctive ANGII versus standard-of-care (SOC) vasopressors alone (norepinephrine, epinephrine, vasopressin, phenylephrine, dopamine). MEASUREMENTS AND MAIN RESULTS: The primary outcome was intensive care unit mortality. Secondary outcomes included 30-day mortality, Sequential Organ Failure Assessment (SOFA) score at 72 hours, time to shock resolution, and adverse effects. A multivariate logistic regression was used for the primary analysis. The study included 265 patients, of which 70 received ANGII and 195 received SOC. Intensive care unit and 30-day mortality were lower in patients that received ANGII (61.4% v 75.4%, adjusted odds ratio 0.438, 95% confidence interval: 0.239-0.805, p = 0.008; and 67.1% v 78.5%, adjusted odds ratio 0.479, 95% confidence interval: 0.256-0.898, p = 0.022). Differences in time to shock reversal and SOFA score at 72 hours were not statistically significant. The adverse effects evaluated were not statistically significant, apart from an increase in fungal infections in the ANGII group (17.1% v 7.2%, p = 0.016). CONCLUSIONS: ANGII was associated with lower mortality in patients who received renal replacement therapy compared to SOC. This evaluation reaffirms a subgroup of patients that may benefit from the addition of ANGII.
3. Level of sedation in patients with COVID-19 supported with ECMO: A comparative analysis of the critical care consortium international database.
In a retrospective VV-ECMO COVID-19 cohort (low-sedation n=224; high-sedation with continuous NMBA n=104), high sedation was associated with markedly higher 90-day in-hospital mortality (HR 3.23). Low-sedation patients had fewer infectious and hemorrhagic complications but longer ECMO runs and more circuit changes.
Impact: Provides real-world evidence suggesting benefit of reduced sedation/avoiding continuous paralysis during VV-ECMO, informing protocols in ICU and ECMO centers.
Clinical Implications: Consider minimizing continuous NMBA exposure and aiming for lighter sedation during VV-ECMO while preparing for longer ECMO runs and more circuit management; randomized trials are needed to confirm causality.
Key Findings
- High-sedation (continuous NMBA) associated with higher 90-day in-hospital mortality (HR 3.23; 95% CI 2.16–4.83).
- Low-sedation patients had fewer infectious and hemorrhagic complications.
- Low sedation resulted in longer ECMO duration and more circuit changes.
Methodological Strengths
- International registry with cause-specific Cox proportional hazards modeling.
- Explicit stratification by sedation strategy and assessment of complications.
Limitations
- Retrospective design with baseline oxygenation differences; unmeasured confounding cannot be excluded.
- Findings specific to COVID-19 VV-ECMO era and may not generalize to non-COVID ARDS.
Future Directions: Prospective, protocolized RCTs comparing light vs deep sedation/continuous paralysis during VV-ECMO with standardized weaning and complication surveillance.
BackgroundLiberation from sedation may be beneficial for patients with acute respiratory distress syndrome supported by veno-venous (VV) extracorporeal membrane oxygenation (ECMO). Currently, there is limited evidence to support this approach. Therefore, this study aimed to compare the 90-day patient mortality of different sedation strategies in COVID-19 patients supported with VV ECMO.MethodsRetrospective, observational sub-study of the COVID-19 Critical Care Consortium database including COVID-19 patients supported with VV ECMO. Two cohorts were compared: high sedation patients who received neuromuscular blocking agents (NMBAs) throughout ECMO and low sedation patients who did not receive NMBA consistently. Patients' level of sedation during ECMO was also considered. The primary outcome was 90-day in-hospital mortality and was assessed using cause-specific Cox proportional hazard models.Results224 low and 104 high sedation patients were included. Pre-ECMO respiratory condition prior was similar between groups, except for the ratio of partial pressure of oxygen to inspired fraction of oxygen, which was lower in the high sedation group at 93 [61-130] than the low sedation group at 106 [69-140]. No difference was observed in disease severity scores between cohorts. Low sedation patients had longer ECMO runs, more circuit changes, but lower infectious and hemorrhagic complications. Higher sedation was associated with a hazard ratio for death of 3.23 (95% CI 2.16-4.83) compared to low sedation.ConclusionsReduced sedation in COVID-19 ECMO patients is feasible and may be associated with improved survival and reduced complications compared to continuous paralysis, albeit with longer ECMO runs.